Revelation Biosciences (REVB)
NASDAQ:REVB
Want to see REVB full AI Analyst Report?
REVB Stock Chart & Stats
$0.90
-$0.04(-6.62%)
At close: 4:00 PM EST
$0.90
-$0.04(-6.62%)
Day’s Range― - ―
52-Week Range$0.88 - $32.16
Previous CloseN/A
Volume326.26K
Average Volume (3M)740.56K
Market Cap
$4.18M
Enterprise Value-$9.17M
Total Cash (Recent Filing)$14.11M
Total Debt (Recent Filing)$759.04K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 07, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.14
Shares Outstanding3,908,420
10 Day Avg. Volume239,834
30 Day Avg. Volume740,557
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-2.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit702.59
Enterprise Value/Ebitda0.91
Forecast
1Y Price Target
$16.00Price Target Upside1677.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-5.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Larger Equity CushionA very low debt-to-equity ratio and a material rise in equity provide durable financial flexibility for a pre-revenue biotech. This reduces default risk, broadens options for funding R&D or trials, and lengthens runway versus peers that rely more heavily on debt financing.
Shareholder-approved Warrant Issuance Increases Funding OptionalityFormal approval of the warrant share issuance and confirmed terms through 2031 give management a durable tool to raise capital or negotiate financings without additional shareholder rule uncertainty. That procedural clarity materially increases long-term capital markets optionality for funding development.
Focused Clinical-stage Innate Immunity PipelineA concentrated R&D focus on innate immunity and intranasal therapeutics targets a defined unmet medical need and can create a defensible niche. If clinical progress continues, the specialized platform and regulatory data could yield sustainable competitive advantages in respiratory and immunology markets.
Bears Say
Zero Reported RevenueNo product revenue means the company remains fully dependent on financing and clinical milestones. Without commercialization traction, long-term sustainability hinges on successful trials or partnerships, making cash needs persistent and business viability contingent on external funding events.
Persistent Cash Burn And Negative Free Cash FlowSustained negative operating and free cash flow creates ongoing funding requirements; although spending improved versus 2024, the company still burns nearly $9M TTM. This structural cash gap requires recurring capital raises, constraining strategic flexibility and increasing dilution risk over time.
Dilution Risk From Warrant IssuanceThe shareholder vote permits large warrant-related share issuance, which can materially dilute existing holders when exercised. Given ongoing losses and funding needs, the practical likelihood of future dilution is elevated, which can weaken per-share economics and investor returns over the medium term.
Revelation Biosciences News
REVB FAQ
What was Revelation Biosciences’s price range in the past 12 months?
Revelation Biosciences lowest stock price was $0.88 and its highest was $32.16 in the past 12 months.
What is Revelation Biosciences’s market cap?
Revelation Biosciences’s market cap is $4.18M.
When is Revelation Biosciences’s upcoming earnings report date?
Revelation Biosciences’s upcoming earnings report date is Aug 07, 2026 which is in 73 days.
How were Revelation Biosciences’s earnings last quarter?
Revelation Biosciences released its earnings results on May 07, 2026. The company reported -$2.71 earnings per share for the quarter, the consensus estimate of -$2.71 by $0.
Is Revelation Biosciences overvalued?
According to Wall Street analysts Revelation Biosciences’s price is currently Undervalued.
Does Revelation Biosciences pay dividends?
Revelation Biosciences does not currently pay dividends.
What is Revelation Biosciences’s EPS estimate?
Revelation Biosciences’s EPS estimate is -0.83.
How many shares outstanding does Revelation Biosciences have?
Revelation Biosciences has 3,908,420 shares outstanding.
What happened to Revelation Biosciences’s price movement after its last earnings report?
Revelation Biosciences reported an EPS of -$2.71 in its last earnings report, expectations of -$2.71. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Revelation Biosciences?
Currently, no hedge funds are holding shares in REVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revelation Biosciences
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
REVB Stock 12 Month Forecast
Average Price Target
$16.00
▲(1677.78% Upside)
Technical Analysis
GT Biopharma
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
Azitra Inc
―
Ownership Overview
8.82% Insiders
0.69% Mutual Funds
10.81% Other Institutional Investors
79.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---